William Dai is the Founding Managing Partner of ShangBay Capital, a leading early stage Medtech-focused VC based in Palo Alto, California. Since the founding of ShangBay Capital in 2015, William has led ShangBay to become a very successful VC with 51 portfolio companies to date and multiple successful exits. William currently sits on the board of several companies, including SetPoint Medical, Aqua Medical, Emboline, Meditrina, Corinth Medtech, FemDx, Apostle, Contraline, Laplace Interventional, and previously sat on the board for NeuroVasc (acq in 2019) and Arrinex (acq by Stryker in 2019).
William’s prior work experiences spans more than 20 years in corporate finance, mergers and acquisitions, and capital markets in both China and the U.S. Prior to founding ShangBay Capital, he was previously the CFO of ShangPharma (NYSE: SHP), China Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation (HK:00853), and Boston Scientific Corporation (China). In these roles, William was responsible for the overall execution and was held accountable to the highest ethical standards in his business dealings. He began his career at the Ford Motor Company in Michigan as a Finance Manager of the Treasury department.
He is well-respected among financial and investment circles and is a recognized leader in the industry. In addition, due to his hands-on experience leading multiple large international medical device companies, he has a very in-depth knowledge of the medical device industry and its market dynamics.
William Dai holds a master’s degree in business administration with an emphasis on finance from Michigan State University.